Across TCGA pan-cancer cohorts, FOXE3 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated FOXE3 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher FOXE3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FOXE3 expression acts as an unfavorable survival marker.

BLCA and LIHC are the cancer types where FOXE3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.248	0.720	.026	9	view →
LIHC	DFS	Median	All	0.161	0.555	.033	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: FOXE3 tumor-vs-normal RNA expression · all FOXE3 data types